The DOI matches its Crossref record; 69 of the 70 references it cites were found in a registry or an index.
Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?
Abstract
Metformin is the most widely used antidiabetic drug in the world, and there is increasing evidence of a potential efficacy of this agent as an anticancer drug. First, epidemiological studies show a decrease in cancer incidence in metformin-treated patients. Second, metformin decreases insulin resistance and indirectly reduces insulin level, a beneficial effect because insulin promotes cancer cell growth. Third, several reports outline a direct inhibitory effect of metformin on cancer cell growth and an antitumoral action. Finally, metformin activates the AMP activated protein kinase (AMPK) pathway, a major sensor of the energetic status of the cell, which has been proposed as a promising therapeutic target in cancer. Mol Cancer Ther; 9(5); 1092–99. ©2010 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 2×
“In diabetic patients, metformin confers cardiovascular protection, an effect not only related to its anti-hyperglycemic effect but also to its favorable action on lipid metabolism (3).”
BackgroundOverweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613 · cited 1×
“Indeed, type II diabetic patients are often overweight or obese, two conditions that favor the incidence of cancers (11).”
BackgroundFatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941 · cited 1×
“Although the Warburg effect has been recognized since the 1920s, less well-appreciated are the alterations in lipid metabolism and the high rates of de novo fatty acid biosynthesis exhibited by many tumors (55).”
BackgroundMetformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“Evans and colleagues were the first to show that metformin treatment is associated with a reduced risk of all cancers (6).”
BackgroundTumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337 · cited 1×
“Metabolic reprogramming from oxidative phosphorylation to glycolysis is a hallmark that constitutes an undisputed advantage for cancer cells and tumor growth (51).”
BackgroundInsulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 1×
“Because insulin is a growth-promoting hormone with mitogenic effects (14), it has been suggested that hyperinsulinemia combined with insulin resistance might promote carcinogenesis (15).”
BackgroundThe Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · cited 1×
“The exact mechanism through which metformin reduces hepatic production requires LKB1/serine threonine kinase 11 (STK11), which controls the AMPK/mammalian target of rapamycin (AMPK/ mTOR) pathway and neoglucogenic genes (4).”
BackgroundFantin, V. R., St-Pierre, J., & Leder, P. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.023 · Cited by 1,635 · cited 1×
“Although this shift to high rates of glycolysis has been considered for many years to be a by-product of the oncogenic process, recent evidence suggests that it is required for malignant progression (52).”
BackgroundAMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399 · cited 1×
“Metformin hampers the respiratory chain complex I in hepatocytes (53).”
Background
Cited by
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Obesity and cancer risk: Emerging biological mechanisms and perspectives
Avgerinos, K. I., Spyrou, N., Mantzoros, C. S., & Dalamaga, M. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.001 · Cited by 1,567
“suggests an anticancer role for metformin, this is challenged by the fact that higher metformin doses are used inmechanistic studies and animal studies, exceeding standard treatment doses in humans [240].”
BackgroundSalminen, A., Hyttinen, J. M. T., & Kaarniranta, K. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0748-0 · Cited by 866
“Metformin is a clinically used AMPK agonist against hyperglycemia in type II diabetes, and it is also a potent anticancer drug in certain types of cancers [102].”
BackgroundCancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth
Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H., & Takeyama, H. (2015) · Cancers · doi:10.3390/cancers7040902 · Cited by 774
“inhibition of the anaerobic glycolytic pathway [90].”
BackgroundMetformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616
“3 INTRODUCTION Metformin a widely used anti-diabetic drug appears to reduce the incidence of cancer in diabetic patients (1), and to inhibit cancer cell proliferation and tumor growth in animal models (2-4).”
BackgroundSelf-citation
Metadata
- Authors
- Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F.
- Affiliations
- Authors' Affiliations: 1INSERM U895, Team 7: Cellular and Molecular Physiopathology of Obesity and Diabetes, 2Université de Nice-Sophia-Antipolis, UFR Médecine, IFR 50, and 3Centre Hospitalier Universitaire de Nice, Hôpital L'Archet, Pôle digestif, Nice, France
- Inserm (FR)
- Venue
- Molecular Cancer Therapeutics
- Published
- 2010-05-01
- Volume
- 9
- Issue
- 5
- Pages
- 1092-1099
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2153980878
- Cited by
- 493
- References
- 70
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 17 · 2023: 17 · 2022: 23 · 2021: 27 · 2020: 16 · 2019: 34 · 2018: 33 · 2017: 40 · 2016: 32 · 2015: 40 · 2014: 61 · 2013: 39 · 2012: 43
- FWCI
- 17.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Association pour la Recherche sur le Cancer
- Centre National de la Recherche Scientifique
- Association pour la Recherche sur les Tumeurs de la Prostate
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- metformin, anticancer drug repurposing, antidiabetic drugs, cancer incidence, insulin resistance, insulin, tumor cell growth inhibition, AMPK, AMPK signaling, anticancer activity
- MeSH terms
- Adenylate Kinase, Animals, Antineoplastic Agents, Humans, Hypoglycemic Agents, Medical Oncology, Metformin, Models, Biological, Neoplasms, Protein Serine-Threonine Kinases, Intracellular Signaling Peptides and Proteins, Cell Proliferation, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug? https://app.cochat.ai/papers/10.1158/1535-7163.mct-09-1186
- The paper
- Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010). Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug? Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-09-1186
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.